Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qiju Granules (杞菊颗粒) is a Traditional Chinese Medicine (TCM) botanical drug candidate developed by Beijing Yingkerui Innovative Drug Research Co., Ltd. It is formulated as granules for oral administration and is currently in Phase II clinical development for the treatment of intermediate age-related macular degeneration (AMD). The drug is specifically indicated for patients diagnosed with the "liver and kidney yin deficiency" syndrome according to TCM principles. The formulation typically centers on extracts of *Lycium barbarum* (Goji berry) and *Chrysanthemum morifolium* (Chrysanthemum), which are traditionally recognized for their ability to nourish the liver and kidneys and improve visual acuity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qiju Granules.